The Quantellect read.As of Nov 19, 2026, 15 active firms cover Uipath Inc: 2 rate it Buy or better, 11 sit at Neutral, and 2 rate it Sell or worse, a neutral consensus. Targets range widely, $10.00 to $23.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $15.67 sits 33% above the current $11.74. Sentiment has cooled somewhat, with Sell ratings rising from 1 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.30 next quarter toward $0.92 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS15 active firms
Neutral
Strong Buy00%
Buy213%
Neutral1173%
Sell213%
Strong Sell00%
Based on 15 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$15.67
+33.4% upside
Average target across 15 active firms as of Nov 19, 2026 vs $11.75 current
Highest Target$23.00
Average Target$15.67
Lowest Target$10.00
Detailed analyst forecasts for PATH
Showing 1–15 of 15 named analysts shown · 15 active firms in the rating projection
As of Nov 19, 2026, 2 of 15 active firms rate PATH a Buy (11 Neutral, 2 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
PATH EPS & revenue forecast
EPS · NEXT QUARTER
$0.30
Range $0.25 – $0.34 · 19 analysts · -1% YoY
Next period, 19 analysts expect Uipath Inc to earn $0.30 a share (range $0.25 – $0.34), versus $0.30 a year earlier. Full-year consensus is $0.79, growing to $0.92 the year after.
REVENUE · NEXT QUARTER
$520.6M
Range $518.8M – $526.9M · 19 analysts · +8% YoY
Revenue is expected to reach $520.6M (range $518.8M – $526.9M), +8.2% year-over-year. Full-year consensus is $1.8B, rising to $1.9B next year.
Top analysts covering Uipath Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PATH.
#1
Raimo Lenschow
Barclays · Rank #432
Neutral
$17.00+44.7% to target
Overall win rate
37%
+ Follow
#2
Michael Turrin
Wells Fargo · Rank #494
Neutral
$15.00+27.7% to target
Overall win rate
35%
+ Follow
#3
Scott Berg
Needham · Rank #575
Buy
$22.00+87.3% to target
Overall win rate
22%
+ Follow
#4
Keith Bachman
BMO Capital
Neutral
$15.00+27.7% to target
Coverage
—
+ Follow
#5
KC
Kingsley Crane
Canaccord Genuity
Neutral
$14.00+19.2% to target
Coverage
—
+ Follow
PATH stock forecast FAQ
What is PATH's average 12-month price target?+
The 15 active firms with a live target average $15.67 for Uipath Inc over the next 12 months, ranging from a $23.00 high to a $10.00 low, as of Nov 19, 2026.
Is PATH stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 15 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 11 rate it Neutral, and 2 rate it Sell or Strong Sell.
What are the highest and lowest price targets for PATH?+
The Street-high target is $23.00 (Citigroup), and the Street-low is $10.00 (DA Davidson). The average of all 15 active-firm targets is $15.67.
How many active Wall Street firms cover PATH?+
15 active firms have a recognized rating on Uipath Inc as of Nov 19, 2026, and 15 active firms carry a live 12-month price target.
Who is the most accurate analyst covering PATH?+
Among analysts who currently cover PATH, Raimo Lenschow of Barclays has the strongest overall Quantellect track record (Rank #432). Their current call is Neutral with a $17.00 target.
What is Uipath Inc's projected EPS for next quarter?+
The consensus estimate is $0.30 per share (range $0.25 – $0.34) across 19 analysts. Full-year EPS is projected at $0.79, rising to $0.92 the following year.
How much revenue is Uipath Inc expected to report next quarter?+
Consensus revenue is $520.6M (range $518.8M – $526.9M). Full-year revenue is projected at $1.8B, growing to $1.9B next year.
Have analysts been upgrading or downgrading PATH lately?+
As of Nov 19, 2026, 2 of 15 active firms rate PATH a Buy (11 Neutral, 2 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PATH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.